Greater than half of sufferers with myelofibrosis with low platelets handled with Vonjo had a platelet response, with median platelets rising 58% and hemoglobin growing.
Greater than half of sufferers with low platelets (thrombocytopenia) handled with Vonjo (pacritinib) had a platelet response, with median platelets rising over 50%, and people who responded additionally noticed hemoglobin improve by greater than 1 g/dL, whereas nonresponders’ platelet and hemoglobin ranges remained steady, in keeping with research findings printed on the 2025 EHA Annual Assembly.
Of the 90 sufferers, 47 (52.2%) skilled a rise in platelets, often known as a platelet response, which implies their platelet counts improved in keeping with established standards. Amongst these 47 sufferers, 33 (70.2%) noticed this enchancment inside 90 days. Most sufferers who responded by day 90 have been male or White and had anemia at the beginning of remedy, just like those that didn’t have a platelet response. Sufferers who responded additionally had greater platelet counts firstly of remedy in comparison with non-responders.
The median time from myelofibrosis prognosis to platelet response was 1.7 months general and 0.9 months for many who responded by day 90. Comply with-up after beginning remedy was longer in sufferers who responded (13 months) than in those that didn’t (11 months). Sufferers who didn’t reply had a barely longer time from prognosis to remedy begin (6.3 months) in comparison with those that responded (4.9 months).
Therapy with Vonjo was comparable between teams, with 42% of responders receiving it as first-line remedy and one other 42% as second-line remedy. Amongst sufferers with a minimum of 9 months of follow-up, the median period of remedy was six months for many who responded and 5.8 months for non-responders.
Platelet counts in sufferers who responded elevated by a median of 58% by day 90 and remained greater at day 180 (41% improve) and day 270 (32% improve). In sufferers who didn’t reply by day 90, platelet counts stayed about the identical via day 180 and elevated by 14% by day 270. Hemoglobin ranges remained steady in each teams via day 180 and elevated by 4% in responders and a pair of.8% in non-responders by day 270.
Six-month survival after day 90 was comparable in each teams: 81% in sufferers who responded and 81% in those that didn’t, together with 14 sufferers who responded after day 90. General survival was constant between early responders and non-responders, suggesting that longer follow-up is required to totally perceive the survival advantages of a platelet response.
What’s the Trial Design?
Researchers reviewed well being data of sufferers with myelofibrosis who have been handled with Vonjo in real-world scientific settings between June 2022 and June 2024. The evaluation targeted on sufferers with low platelet counts at the beginning of remedy who had a minimum of three months of follow-up knowledge.
Platelet response was outlined as a significant improve in platelet counts after beginning remedy. Sufferers who reached this response inside three months have been highlighted individually.
Researchers additionally tracked hemoglobin ranges and general survival, which is the size of time sufferers lived after beginning remedy, from three months after remedy started. Outcomes have been summarized to point out typical experiences with Vonjo in each day apply.
What’s Myelofibrosis?
Myelofibrosis is a uncommon blood most cancers that may trigger signs like fatigue, fever, weight reduction, bleeding and bone ache. It could additionally result in an enlarged spleen, a danger of progressing to leukemia and shorter life expectancy.
Many sufferers with myelofibrosis have low platelet counts, which is linked to the next danger of problems.
Vonjo is a medicine accredited in the USA to deal with sufferers with myelofibrosis who’ve very low platelet counts. In scientific research, Vonjo may help stabilize platelet ranges and typically enhance them, although real-world knowledge on how blood counts reply exterior of scientific trials is restricted.
Reference
- “HEMATOLOGIC IMPROVEMENT EXPERIENCED BY PACRITINIB-TREATED PATIENTS WITH MYELOFIBROSIS IN REAL-WORLD CLINICAL SETTINGS,” by Dr. Michael Marrone, et al. 2025 EHA Annual Assembly.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
